Doublle Bioproduct

Company Drug

Guangzhou Doublle Bioproduct Receives IND Approval for E101 in Type 2 Diabetes

Fineline Cube Mar 26, 2025

Guangzhou Doublle Bioproduct Co., Ltd. has announced receiving Investigational New Drug (IND) clearance from China’s...

Company Drug

Shionogi Submits Rolling NDA for Ensitrelvir in US for COVID-19 Prophylaxis

Policy / Regulatory

China’s National Health Commission Outlines Key Tasks for Primary Healthcare Reform in 2025

Company Drug

Pfizer Expands Abrysvo RSV Vaccine Indication to Include Ages 18-59 in EU

Company Drug Legal / IP

AccurEdit’s ARTbase-A1 Base Editor Authorized by USPTO